4D Molecular Therapeutics Completes Phase-3 Enrollment

4D Molecular Therapeutics announced on February 9 that it completed enrollment in 4FRONT-1, the Phase 3 trial of intravitreal 4D-150 for wet age-related macular degeneration. The randomized, double-masked study compares 4D-150 to aflibercept with a primary non-inferiority endpoint in mean change in best corrected visual acuity at 52 weeks. Barclays initiated Overweight coverage on January 27 with a $33 price target.